Downregulation of klotho β is associated with invasive ductal carcinoma progression

Li,Ping; Zhao,Meng; Qi,Xiaoli; Zhu,Xuegong; Dai,Jie

doi:10.3892/ol.2017.7110

Downregulation of klotho β is associated with invasive ductal carcinoma progression

Authors:
- Ping Li
- Meng Zhao
- Xiaoli Qi
- Xuegong Zhu
- Jie Dai
View Affiliations

Affiliations: Department of Pathology, Capital Medical University, Beijing 100069, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/ol.2017.7110
Pages: 7443-7448

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Klotho β (KLB) is a single‑pass transmembrane protein measuring 1,043 amino acids in length that shares 41.2% homology with klotho α (KLA). KLB is a co‑receptor and key regulator of the fibroblast growth factor receptor 4 (FGFR4) pathway. KLB interacts with FGFR4 to induce apoptosis and inhibit the proliferation of hepatoma cells, and KLA has been demonstrated to be a tumor suppressor in human breast cancer; however, little is known regarding the role of KLB in breast cancer. In the present study, through an immunohistochemical analysis of invasive ductal carcinoma tissue arrays, low KLB expression was identified in invasive ductal carcinoma samples compared with paired adjacent non‑tumorous breast tissues (82 cases). In invasive ductal carcinoma tissues, KLB expression was negatively associated with pathological grade and lymph node metastasis. In 42 cases of paired microdissected breast specimens, the condition of the KLB gene allele was examined to determine the loss of heterozygosity (LOH), and selective LOH was identified at the KLB locus in 57.1% of primary tumors. These data suggest that KLB may be associated with the progression and metastasis of invasive ductal carcinoma, and therefore have clinical and therapeutic importance.

View Figures

View References

1	Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Estimated cancer incidence, mortality and prevalence worldwide: IARC CancerBase No. 11 (Internet)International Agency for Research on Cancer. Lyon, France: 2014, http://globocan.iarc.fr/pages/fact_sheets_population.aspx?country=900October 9–2014
2	National Cancer Institute: Breast Cancer Treatment (PDQ^®)–Patient Version. https://www.cancer.gov/types/breast/patient/breast-treatment-pdqUpdated May 5, 2017.
3	Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 390:45–51. 1997. View Article : Google Scholar
4	Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M and Nabeshima Y: Identification of the human Klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem Biophys Res Commun. 242:626–630. 1998. View Article : Google Scholar
5	Shiraki-Iida T, Aizawa H, Matsumura Y, Sekine S, Iida A, Anazawa H, Nagai R, Kuro-o M and Nabeshima Y: Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett. 424:6–10. 1998. View Article : Google Scholar
6	Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP and Rubinek T: Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 27:7094–7105. 2008. View Article : Google Scholar
7	Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T and Nabeshima YI: Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev. 98:115–119. 2000. View Article : Google Scholar
8	Ito S, Fujimori T, Furuya A, Satoh J and Nabeshima Y and Nabeshima Y: Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest. 115:2202–2208. 2005. View Article : Google Scholar
9	Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, Eliseenkova AV, Mohammadi M and Kuro-o M: BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA. 104:pp. 7432–7437. 2007, View Article : Google Scholar
10	Fukumoto S: Actions and mode of actions of FGF19 subfamily members. Endocr J. 55:23–31. 2008. View Article : Google Scholar
11	Tomiyama K, Maeda R, Urakawa I, Yamazaki Y, Tanaka T, Ito S, Nabeshima Y, Tomita T, Odori S, Hosoda K, et al: Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci USA. 107:pp. 1666–1671. 2010, View Article : Google Scholar
12	Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA and Kuro-o M: Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 282:26687–26695. 2007. View Article : Google Scholar
13	Lin BC, Wang M, Blackmore C and Desnoyers LR: Liver-specific activities of FGF19 require Klotho beta. J Biol Chem. 282:27277–27284. 2007. View Article : Google Scholar
14	Luo Y, Yang C, Lu W, Xie R, Jin C, Huang P, Wang F and McKeehan WL: Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. J Biol Chem. 285:30069–30078. 2010. View Article : Google Scholar
15	Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu W, Yang Y and Chen G: βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/Cyclin D1 signaling pathway. PLoS One. 8:e556152013. View Article : Google Scholar
16	Zhu X, Zheng L, Asa SL and Ezzat S: Loss of Heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. Am J Pathol. 177:2860–2869. 2010. View Article : Google Scholar
17	Lakhani Sunil R: International Agency for Research on CancerWorld Health Organization. Lyon: International Agency for Research on Cancer; 2012
18	Marusyk A, Almendro V and Polyak K: Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer. 12:323–334. 2012. View Article : Google Scholar
19	Yang CY, Lu RH and Lin CH, Jen CH, Tung CY, Yang SH, Lin JK, Jiang JK and Lin CH: Single nucleotide polymorphisms associated with colorectal cancer susceptibility and loss of heterozygosity in a taiwanese population. PLoS One. 9:e1000602014. View Article : Google Scholar
20	Chen B, Wang X, Zhao W and Wu J: Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res. 29:992010. View Article : Google Scholar
21	Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, et al: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 286:8655–8665. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kotepui M, Thawornkuno C, Chavalitshewinkoon-Petmitr P, Punyarit P and Petmitr S: Quantitative real-time RT-PCR of ITGA7, SVEP1, TNS1, LPHN3, SEMA3G, KLB and MMP13 mRNA expression in breast cancer. Asian Pac J Cancer Prev. 13:5879–5882. 2012. View Article : Google Scholar : PubMed/NCBI
23	Poh W, Wong W, Ong H, Aung MO, Lim SG, Chua BT and Ho HK: Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth receptor-4 signaling in hepatocellular carcinoma. Mol Cancer. 11:142012. View Article : Google Scholar : PubMed/NCBI